The SynGAP Research Fund awarded grants to Dr. Clement Chow to advance therapeutic development for SYNGAP1-Related Disorders (SRD). Using a fruit fly model, Chow's team identified N-acetyl-L-leucine (NALL) as a promising treatment candidate. The follow-up grant supports further validation of NALL's therapeutic potential, aiming to fast-track treatments for SRD through drug repurposing.